Curasight has received positive results from a Phase 2 study of uTRACE in aggressive brain cancer, validating the technology and opening up combination therapies with
In May, the current CEO of Ekobot resigned from his position, causing turmoil and a falling share price. The company has now found its new
Mdundo is guiding for strong growth for the 2023/24 financial year and remains on course for its long-term goals in 2025. Will this also put
Despite a revenue in H1 22/23 of DKK 0.3 million (DKK 0.2 million) CS Medica maintains the expectation for the year’s revenue growth of 120-130%
Ekobot’s Q1 2023 report was as expected and the investment case with focus on further sales and commercialization of the agricultural robots is therefore intact
Curasight and Curium of France have entered into a partnership agreement for uTRACE for prostate cancer. This has triggered a significant price trigger, and Curasight
CS Medica has achieved positive results of a clinical study with its pain patch with CBD. With clinical proof of efficacy, the possibilities are fot
The Q3 report (January-March 2023) from Mdundo shows a high user growth to 24.5 million monthly active users, which has led the company to raise
The 2022 annual report from EKOBOT is without information that can have a significant price impact and after the recent successful rights issue, it would
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an antifungal drug that is more
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.